WATERTOWN, Mass. --(BUSINESS WIRE)--Mar. 2, 2021-- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT)

Thought leader in the ENT treatment community brings insight from clinical practice to next stage of development for LYR-210 and pipeline WATERTOWN, Mass. --(BUSINESS WIRE)--Feb. 17, 2021-- Lyra Therapeutics, Inc . (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and

WATERTOWN, Mass. --(BUSINESS WIRE)--Jan. 22, 2021-- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT)